Insmed CEO Defends BRINSUPRI Launch as Sales Surge, TPIP Pipeline Gains Focus Insmed (
NASDAQ:INSM ) Chair and CEO Will Lewis said the company remains confident in the launch trajectory of BRINSUPRI, despite investor concerns over discontinuation rates that followed the company’s latest update. Speaking at a Bank of America healthcare conference, Lewis said the company intended
Patient Square Makes a Big Bet on Nektar Pharmaceuticals (NKTR) Purchasing 210,000 Shares This biotech firm develops immunotherapies for cancer and autoimmune diseases, with several candidates advancing through clinical trials.
This Nuclear Tech Stock Grew Revenue 27%, But a Fund Still Slashed Its Stake Mirion Technologies delivers radiation detection and monitoring solutions to healthcare and industrial clients worldwide.
This Retail Stock Is Down 10% in a Year Despite Record Revenue. A Fund Just Cut Its Stake This global retailer offers apparel and accessories across multiple brands and channels in North America, Europe, and Asia.
This Trade School Stock Is Up 135%. Here’s Why a Fund Still Bought 459,000 Shares Lincoln Educational Services delivers hands-on technical and healthcare training across 22 campuses, serving workforce needs nationwide.
Callaway Stock Has Soared 150%. Here’s Why One Fund Still Bought 1.1 Million Shares Callaway Golf Company combines branded equipment sales with experiential entertainment through its Topgolf venues and lifestyle offerings.
This New $193 Million Bet Targets a Biotech With $689 Million in Revenue and a Potential Turnaround Story This biotech firm develops therapies for rare, complement-driven diseases, with a focus on autoimmune and inflammatory conditions.
This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug Launch Cogent Biosciences develops targeted therapies for genetically defined diseases, focusing on precision medicine for rare cancers.
This Specialized Heart Monitor Maker Just Caught the Eye of a Major Healthcare Fund RTW Investments loads up on iRhythm Holdings with 1.18M Shares Worth $210 million. iRhythm delivers wearable cardiac monitoring and analytics solutions to healthcare providers and at-risk patients.
This $91 Million Position Signals Conviction in a Biotech Stock Eyeing FDA Decision This Year This clinical-stage biotech develops therapies for serious immunological diseases, with a focus on late-stage biologic candidates.
The Small-Cap Renaissance: Why the Russell 2000 is Leading the Charge in 2026 As of March 9, 2026, a dramatic regime shift is unfolding on Wall Street. After years of playing second fiddle to the "Magnificent Seven" and AI-driven mega-caps, small-cap stocks have emerged as the surprise leaders of the 2026 market. The Russell 2000 Index (NYSEArca: IWM) has surged over 6% year-to-date,
Investment Manager Bets Big on PTCT Stock, Adds 41,000 Shares, According to Recent SEC Filing PTC Therapeutics develops therapies for rare diseases, with a portfolio spanning commercial products and investigational candidates.
Investment Firm Adds Nearly $4 Milllion Worth of DYN Shares, According to Recent SEC Filing This clinical-stage biotech develops therapies for rare muscle diseases using its proprietary FORCE platform and research-driven approach.
Investment Advisor Bets Big on CMPX Stock, Adds 2.5 Million Shares, According to Latest SEC Filing This clinical-stage biotech develops antibody therapeutics targeting cancer, with a pipeline focused on oncology and immunotherapy markets.
Investor Buys Up $81 Million in Praxis Stock as Shares Soar Over 300% in One Year Praxis Precision Medicines develops therapies for neurological and psychiatric disorders, aiming to address unmet needs in the CNS market.
This Fund Bet Nearly $40 Million on GRAIL Last Quarter. The Stock Just Plunged Over 50% GRAIL develops advanced cancer detection technologies, serving healthcare providers and individuals seeking early diagnostic solutions.
Biotech Exit: $26 Million Arcellx Sale Follows Tepid Stock Performance and Kelonia Competition Arcellx develops cell-based immunotherapies targeting cancer, with a lead candidate in early-stage trials for multiple myeloma.
Cogent Biosciences Stock Up 346% as Fund Builds $29 Million Stake After November Phase 3 Breakthrough Cogent Biosciences develops precision therapies for genetically defined diseases, with a pipeline targeting rare oncological conditions.
Fund Discloses $35 Million Biotech Buy Amid Staggering 830% Terns Stock Surge This clinical-stage biotech develops therapies for NASH and obesity, advancing a diverse pipeline of small-molecule drug candidates.
Biotech Stock Up 266%: This New $55 Million Bet Signals Conviction in Praxis Amid Pipeline Progress Praxis Precision Medicines develops therapies for central nervous system disorders, with candidates targeting depression and epilepsy.
Apogee Stock Jumps 87% in One Year as This Biotech Fund Lifts Stake to $93 Million This clinical-stage biotech develops monoclonal antibody therapies targeting chronic inflammatory and immunological diseases.
Stock Market Today, Jan. 6: Alumis Shares Surge on Positive Phase 3 Psoriasis Data for Envudeucitinib Investors today are cheering envudeucitinib's Phase 3 edge in oral TYK2 psoriasis as well as Alumis' plans to raise fresh capital.
